In the oncology sector, Liquid Biopsies—genetic tests that detect circulating tumor DNA in a simple blood draw—have revolutionized cancer surveillance. These tests can identify a cancer recurrence months before a tumor is large enough to be visible on an MRI or CT scan.
As the cost of Whole Genome Sequencing (WGS) continues to drop, the discussion has turned toward the ethical management of "secondary findings." Society is currently grappling with how much information a patient should receive regarding late-onset conditions, such as Alzheimer's, for which there may not yet be a definitive cure.
9 Views